Ironwood names Jeffrey Silber chief medical officer, succeeding Michael Shetzline
IRWD•Silber's background
He joins from Vedanta Biosciences, where he served as chief medical officer since 2020, leading microbiome-based GI therapy development.
Earlier roles included senior vice president in clinical development at EMD Serono/Merck KGaA, vice president at AbbVie, and leadership posts at Merck.
Leadership change in medical affairs
Ironwood named Jeffrey Silber chief medical officer, head of research and drug development, succeeding retiring CMO Michael Shetzline.
Silber starts July 20, 2026; Shetzline will stay on as an advisor during the transition.
Silber will oversee research and drug development, regulatory affairs, medical affairs, reporting to CEO Tom McCourt.
